<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04067011</url>
  </required_header>
  <id_info>
    <org_study_id>EBS.AVA.210</org_study_id>
    <nct_id>NCT04067011</nct_id>
  </id_info>
  <brief_title>Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study</brief_title>
  <official_title>A Phase 2 Drug-Vaccine Interaction Study to Examine Whether Co-administering AV7909 With Ciprofloxacin or Doxycycline Affects Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or&#xD;
      doxycycline when administered orally, prior to, and following, the intramuscular (IM)&#xD;
      administration of a two-dose schedule of AV7909 administered two weeks apart.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, multicenter, randomized trial designed to evaluate the&#xD;
      pharmacokinetic profile, immunogenicity, and safety of AV7909 and ciprofloxacin or&#xD;
      doxycycline when administered concomitantly in healthy adults for an indication of&#xD;
      post-exposure prophylaxis (PEP) of anthrax.&#xD;
&#xD;
      Healthy adults between 18 to 45 years of age (inclusive) will sign and date an informed&#xD;
      consent form and then be screened for eligibility for participation in the study 2 to 28 days&#xD;
      prior to randomization. Participants meeting the entry criteria will be randomized 1:1:1 to&#xD;
      one of the three study groups (AV7909 + ciprofloxacin, AV7909 + doxycycline and AV7909 only)&#xD;
      on Day 1.&#xD;
&#xD;
      Subjects randomized into Groups 1 &amp; 2 will be assigned to subgroups. Subgroup A will be&#xD;
      assigned to the antibiotic PK treatment group first, while subgroup B will be assigned to the&#xD;
      antibiotic non-PK treatment group.&#xD;
&#xD;
      Participants will be evaluated for safety through Day 51 [or the early withdrawal visit&#xD;
      (EWV)], as assessed by clinical laboratory tests (hematology, serum chemistry, and&#xD;
      urinalysis), monitoring of Adverse Events (AEs) including Serious Adverse Events (SAEs) and&#xD;
      Adverse Events of Special Interest (AESIs), vital signs, and physical examinations. Adverse&#xD;
      Events of Special Interest are adverse events associated with autoimmune disease as defined&#xD;
      by the Center for Biologics Evaluation and Research, and might represent a safety signal for&#xD;
      vaccine-associated autoimmunity. Reactogenicity (solicited systemic and injection site&#xD;
      reactions) will be assessed daily by the participants using electronic diaries (e-diaries)&#xD;
      after each vaccination. The e-diary will also be used to record self-administration of&#xD;
      antibiotics for applicable study groups.&#xD;
&#xD;
      Information on the use of medications will be collected at each study visit. In addition,&#xD;
      blood samples for auto-antibody assessment will be taken at Day 1 pre-dose and Day 51 (or&#xD;
      Early Withdrawal Visit).&#xD;
&#xD;
      Participants who receive at least one dose of vaccine will also be asked to participate in&#xD;
      safety follow-up phone calls occurring on Month 3, Month 6, Month 9, and Month 12 (nominally&#xD;
      3, 6, 9, and 12 months after the last vaccination) to collect information on AEs, SAEs and&#xD;
      any potential AESIs. Based on responses at these phone contacts, participants may be asked to&#xD;
      return to the clinic for an unscheduled visit to provide blood samples for auto-antibody&#xD;
      testing to investigate reports of potential AESIs.&#xD;
&#xD;
      Independent safety oversight will be provided by a Data Safety Monitoring Board, which will&#xD;
      be notified of significant AEs, potential AEsIs, or any other events as determined by the&#xD;
      Medical Monitor, on an ongoing basis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Actual">March 19, 2020</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of Ciprofloxacin Area Under the Curve From 0 to 12 Hours (AUC0-12h) and Maximum Concentration (Cmax) on Days 8 and 35</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-ciprofloxacin dose on Days 8 (pre-AV7909 vaccination) and 35 (post-AV7909 vaccination)</time_frame>
    <description>Based on serum concentrations of ciprofloxacin on Day 8 (pre-AV7909 vaccination) and on Day 35 (post-AV7909 vaccination), steady state AUC0-12h and Cmax were derived, and geometric mean of ratio of AUC0-12h on Day35/Day 8 and geometric mean of ratio for Cmax on Day 35/Day8, and the corresponding 90% CI of the mean ratios were calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Doxycycline Area Under the Curve From 0 to 12 Hours (AUC0-12h) and Maximum Concentration (Cmax) on Days 8 and 38</measure>
    <time_frame>Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-doxycycline dose on Days 8 (pre-AV7909 vaccination) and 38 (post-AV7909 vaccination)</time_frame>
    <description>Based on serum concentrations of doxycycline on Day 8 (pre-AV7909 vaccination) and on Day 38 (post-AV7909 vaccination), steady state AUC0-12h and Cmax were derived, and geometric mean of ratio of AUC0-12h on Day38/Day 8 and geometric mean of ratio for Cmax on Day 38/Day8, and the corresponding 90% CI of the mean ratios were calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean TNA 50% Neutralizing Factor (NF50) Values Two Weeks After the Second AV7909 Vaccination (Day 37 ± 1 Day).</measure>
    <time_frame>Day 37 ± 1 day</time_frame>
    <description>Immunogenicity response as assessed by geometric mean of TNA NF50 values at Day 37 (two weeks after second dose of AV7909 vaccination).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Anthrax</condition>
  <arm_group>
    <arm_group_label>Group 1:Ciprofloxacin + AV7909</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.&#xD;
Group 1 will concomitantly receive ciprofloxacin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Doxycycline +AV7909</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.&#xD;
Group 2 will concomitantly receive doxycycline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: AV7909</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin 500Mg Tablet</intervention_name>
    <description>Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.</description>
    <arm_group_label>Group 1:Ciprofloxacin + AV7909</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 100Mg Tablet</intervention_name>
    <description>Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.</description>
    <arm_group_label>Group 2: Doxycycline +AV7909</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AV7909</intervention_name>
    <description>0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.</description>
    <arm_group_label>Group 1:Ciprofloxacin + AV7909</arm_group_label>
    <arm_group_label>Group 2: Doxycycline +AV7909</arm_group_label>
    <arm_group_label>Group 3: AV7909</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained from the participant (dated, signed, and captured in&#xD;
             the medical chart at the site).&#xD;
&#xD;
          2. A male or female, aged 18 to 45 years of age, inclusive, at the time of informed&#xD;
             consent.&#xD;
&#xD;
          3. Healthy condition as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          4. Body mass index (BMI) less than or equal to 35.0 kg/m^2 at the Screening visit.&#xD;
&#xD;
          5. Have adequate venous access for phlebotomies.&#xD;
&#xD;
          6. For a woman of childbearing potential (WOCBP), negative pregnancy test at Screening&#xD;
             and pre-randomization on Day 1, not currently breastfeeding, and no intention to&#xD;
             become pregnant during the study period through 12 months after last receipt of any&#xD;
             investigational product (IP). Every female participant is considered to be a WOCBP&#xD;
             unless she is surgically sterile (hysterectomy, bilateral salpingectomy or bilateral&#xD;
             oophorectomy) OR postmenopausal (defined as &gt;12 consecutive months without menses and&#xD;
             screen follicle-stimulating hormone &gt; 30 mIU/mL). Women who are not of childbearing&#xD;
             potential are allowed to enroll if they are surgically sterile or postmenopausal as&#xD;
             defined above.&#xD;
&#xD;
        Female participants randomized to Groups 1 or 2 must be willing to add a double-barrier&#xD;
        method, IUD, or abstinence as back-up forms of birth control since ciprofloxacin and&#xD;
        doxycycline may decrease the effectiveness of birth control pills, implantable or&#xD;
        injectable contraceptives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A Screening clinical laboratory test result greater than the central laboratory's&#xD;
             upper limit of normal (ULN) for aspartate aminotransferase (AST), alanine&#xD;
             aminotransferase (ALT), random glucose, total bilirubin, blood urea nitrogen (BUN), or&#xD;
             creatinine. Other serum chemistry parameters that are not within the reference range&#xD;
             will not be considered exclusionary unless deemed clinically significant by the&#xD;
             principal investigator.&#xD;
&#xD;
          2. History of allergic reaction or intolerance to quinolone antimicrobials or any medical&#xD;
             condition that would contraindicate the use of ciprofloxacin, including and not&#xD;
             limited to vascular disorders, tendon disorders, certain genetic connective tissue&#xD;
             disorders (e.g., Marfan and Ehlers-Danlos syndrome), prolongation of QT interval,&#xD;
             seizures, peripheral neuropathy, increased risk of C. difficile infection.&#xD;
&#xD;
          3. History of allergic reaction or intolerance to tetracycline antibiotics or any medical&#xD;
             condition that would contraindicate the use of doxycycline including an increased risk&#xD;
             of C. difficile infection, increases in BUN or an increased sensitivity to direct&#xD;
             sunlight or ultraviolet radiation resulting in erythema.&#xD;
&#xD;
          4. Has a need for any of the prohibited medications or requires the medications/foods&#xD;
             within the prohibited times.&#xD;
&#xD;
          5. Have a tattoo/scar/birthmark or any other skin condition affecting the deltoid area&#xD;
             that may interfere with injection site assessments.&#xD;
&#xD;
          6. History of anthrax disease, suspected exposure to anthrax, or previous vaccination&#xD;
             with any anthrax vaccine.&#xD;
&#xD;
          7. Have previously served in the military any time after 1990 or plan to enlist in the&#xD;
             military any time from Screening through the final telephone contact.&#xD;
&#xD;
          8. Previous anaphylactic reaction, severe systemic response, or serious hypersensitivity&#xD;
             to a prior immunization or a known allergy to synthetic ODNs, aluminum, formaldehyde,&#xD;
             benzethonium chloride (phemerol).&#xD;
&#xD;
          9. Plan to have an elective surgery at any point during the study until after the final&#xD;
             safety phone contact.&#xD;
&#xD;
         10. Have donated or plan to donate blood within one month prior to enrollment or at any&#xD;
             point during the study until after the final safety phone contact.&#xD;
&#xD;
         11. Use of any investigational or non-registered product (drug, vaccine or biologic)&#xD;
             within 30 days preceding the dose of study vaccine, or planned use during the study&#xD;
             until after the final safety phone contact.&#xD;
&#xD;
         12. Planned administration of any commercially-available vaccine from one week prior to&#xD;
             the first study vaccination through two weeks after the last vaccination.&#xD;
&#xD;
         13. Have experienced chronic dosing (defined as more than 14 days) with any&#xD;
             immune-modifying drugs within six months of study enrollment. This includes oral,&#xD;
             intramuscular, intra-articular, intravenous, or inhalation corticosteroids except in&#xD;
             the case of inhaled or intranasal medications for seasonal allergies.&#xD;
&#xD;
         14. Receipt of immunoglobulins and/or any blood products within the three months preceding&#xD;
             study enrollment or at any point during the study period until after the final safety&#xD;
             visit on Day 51.&#xD;
&#xD;
         15. An abnormal electrocardiogram (ECG) at screening interpreted as 'Abnormal,&#xD;
             Significant'. Inclusion of participants with 'Abnormal, Insignificant' ECGs will be&#xD;
             based on the principal investigator's discretion.&#xD;
&#xD;
         16. Have an active malignancy or history of metastatic or hematologic malignancy.&#xD;
&#xD;
         17. Have a history of an autoimmune, inflammatory, vasculitic or rheumaticor rheumatic&#xD;
             disease including but not limited to systemic lupus erythematosus, Guillain-Barré&#xD;
             syndrome, myasthenia gravis, polymyalgia rheumatica, diabetes mellitus type I,&#xD;
             rheumatoid arthritis or scleroderma.&#xD;
&#xD;
         18. A positive laboratory evidence of hepatitis B, hepatitis C, or human immunodeficiency&#xD;
             virus (HIV) HIV-1 or HIV-2 infection.&#xD;
&#xD;
         19. Positive result on urine drug screen, any evidence of ongoing drug abuse or dependence&#xD;
             (including alcohol), or recent history (over the past five years) of treatment for&#xD;
             alcohol or drug abuse.&#xD;
&#xD;
         20. Has an acute disease at the time of enrollment.&#xD;
&#xD;
         21. Any medical condition that, in the opinion of the investigator, could adversely impact&#xD;
             the participant's involvement or the conduct of the study.&#xD;
&#xD;
         22. Have a significant chronic condition, e.g., serious cardiovascular, pulmonary,&#xD;
             hepatic, type II diabetes mellitus or renal disease that, in the opinion of the&#xD;
             investigator, would render treatment unsafe or would interfere with trial evaluations&#xD;
             or completion of the study.&#xD;
&#xD;
         23. An opinion of the investigator that it would be unwise to allow the participant to be&#xD;
             randomized into the study.&#xD;
&#xD;
         24. Member or immediate family member of an investigator site team.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research / Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <results_first_submitted>May 14, 2021</results_first_submitted>
  <results_first_submitted_qc>June 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Ciprofloxacin</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>CPG 7909</keyword>
  <keyword>Bacillus anthracis</keyword>
  <keyword>Anthrax Vaccine Adsorbed</keyword>
  <keyword>Post-exposure Prophylaxis</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT04067011/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT04067011/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT04067011/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1:Ciprofloxacin + AV7909</title>
          <description>Group 1 concomitantly received ciprofloxacin and AV7909.&#xD;
Ciprofloxacin 500Mg Tablet: Ciprofloxacin 500mg was administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 4-9, 22-24 and 31-37.&#xD;
AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Doxycycline +AV7909</title>
          <description>Group 2 concomitantly received doxycycline and AV7909.&#xD;
Doxycycline 100mg Tablet: Doxycycline 100mg was administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 2-9, 22-24 and 32-38.&#xD;
AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: AV7909</title>
          <description>AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat population: all subjects who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1:Ciprofloxacin + AV7909</title>
          <description>Group 1 concomitantly received ciprofloxacin and AV7909.&#xD;
Ciprofloxacin 500mg Tablet: Ciprofloxacin 500mg was administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 4-9, 22-24 and 31-37.&#xD;
AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Doxycycline +AV7909</title>
          <description>Group 2 concomitantly received doxycycline and AV7909.&#xD;
Doxycycline 100mg Tablet: Doxycycline 100mg was administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 2-9, 22-24 and 32-38.&#xD;
AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: AV7909</title>
          <description>AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18 - 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 - 45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.1" spread="9.8"/>
                    <measurement group_id="B2" value="169.1" spread="8.5"/>
                    <measurement group_id="B3" value="169.7" spread="10.7"/>
                    <measurement group_id="B4" value="169.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.7" spread="16.7"/>
                    <measurement group_id="B2" value="79.4" spread="12.6"/>
                    <measurement group_id="B3" value="75.0" spread="16.0"/>
                    <measurement group_id="B4" value="77.7" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" spread="4.9"/>
                    <measurement group_id="B2" value="27.7" spread="3.7"/>
                    <measurement group_id="B3" value="25.9" spread="4.6"/>
                    <measurement group_id="B4" value="26.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Ciprofloxacin Area Under the Curve From 0 to 12 Hours (AUC0-12h) and Maximum Concentration (Cmax) on Days 8 and 35</title>
        <description>Based on serum concentrations of ciprofloxacin on Day 8 (pre-AV7909 vaccination) and on Day 35 (post-AV7909 vaccination), steady state AUC0-12h and Cmax were derived, and geometric mean of ratio of AUC0-12h on Day35/Day 8 and geometric mean of ratio for Cmax on Day 35/Day8, and the corresponding 90% CI of the mean ratios were calculated.</description>
        <time_frame>Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-ciprofloxacin dose on Days 8 (pre-AV7909 vaccination) and 35 (post-AV7909 vaccination)</time_frame>
        <population>The number of analyzed participants represents the number of participants that met pre-specified protocol criteria for inclusion in the PK analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin + AV7909</title>
            <description>Participants meeting entry criteria were randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 each received a manufactured lot of AV7909 per the study visit schedule.&#xD;
Group 1 concomitantly received ciprofloxacin.&#xD;
Ciprofloxacin 500Mg Tablet: Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 4-9, 22-24 and 31-37.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Ciprofloxacin Area Under the Curve From 0 to 12 Hours (AUC0-12h) and Maximum Concentration (Cmax) on Days 8 and 35</title>
          <description>Based on serum concentrations of ciprofloxacin on Day 8 (pre-AV7909 vaccination) and on Day 35 (post-AV7909 vaccination), steady state AUC0-12h and Cmax were derived, and geometric mean of ratio of AUC0-12h on Day35/Day 8 and geometric mean of ratio for Cmax on Day 35/Day8, and the corresponding 90% CI of the mean ratios were calculated.</description>
          <population>The number of analyzed participants represents the number of participants that met pre-specified protocol criteria for inclusion in the PK analysis population.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ratios of AUC0-12h (Post-vac./Pre-vac)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9764" lower_limit="0.8895" upper_limit="1.0718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratios of Cmax (Post-vac./Pre-vac)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9706" lower_limit="0.8693" upper_limit="1.0838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of Geometric mean ratio of area under the curve from 0 to 12 hours (AUC0-12h) for ciprofloxacin on Days 8 and 35</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence testing was constructed using paired two one-sided t-tests (TOST) with natural log transformation of PK parameters. Results obtained from transformed analyses were back-transformed by exponentiation for presentation of the point estimates and 90% CIs for geometric mean ratio of AUC0-12h.</non_inferiority_desc>
            <param_type>Ratio of AUC</param_type>
            <param_value>0.9764</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8895</ci_lower_limit>
            <ci_upper_limit>1.0718</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of Geometric mean ration of Cmax for ciprofloxacin on Days 8 and 35</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence testing was constructed using paired two one-sided t-tests (TOST) with natural log transformation of PK parameters. Results obtained from transformed analyses were back-transformed by exponentiation for presentation of the point estimates and 90% CIs for geometric mean ratio of Cmax.</non_inferiority_desc>
            <param_type>Ratio of Cmax</param_type>
            <param_value>0.9706</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8693</ci_lower_limit>
            <ci_upper_limit>1.0838</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Doxycycline Area Under the Curve From 0 to 12 Hours (AUC0-12h) and Maximum Concentration (Cmax) on Days 8 and 38</title>
        <description>Based on serum concentrations of doxycycline on Day 8 (pre-AV7909 vaccination) and on Day 38 (post-AV7909 vaccination), steady state AUC0-12h and Cmax were derived, and geometric mean of ratio of AUC0-12h on Day38/Day 8 and geometric mean of ratio for Cmax on Day 38/Day8, and the corresponding 90% CI of the mean ratios were calculated.</description>
        <time_frame>Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-doxycycline dose on Days 8 (pre-AV7909 vaccination) and 38 (post-AV7909 vaccination)</time_frame>
        <population>The number of analyzed participants represents the number of participants that met pre-specified protocol criteria for inclusion in the PK analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline + AV7909</title>
            <description>Group 2 concomitantly received doxycycline. Doxycycline 100mg Tablet: Doxycycline 100mg was administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 2-9, 22-24 and 32-38.&#xD;
AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Doxycycline Area Under the Curve From 0 to 12 Hours (AUC0-12h) and Maximum Concentration (Cmax) on Days 8 and 38</title>
          <description>Based on serum concentrations of doxycycline on Day 8 (pre-AV7909 vaccination) and on Day 38 (post-AV7909 vaccination), steady state AUC0-12h and Cmax were derived, and geometric mean of ratio of AUC0-12h on Day38/Day 8 and geometric mean of ratio for Cmax on Day 38/Day8, and the corresponding 90% CI of the mean ratios were calculated.</description>
          <population>The number of analyzed participants represents the number of participants that met pre-specified protocol criteria for inclusion in the PK analysis population.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ratios of AUC0-12h (Post-vac./Pre-vac)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9173" lower_limit="0.8187" upper_limit="1.0278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratios of Cmax (Post-vac./Pre-vac)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8974" lower_limit="0.7841" upper_limit="1.0271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of Geometric mean ratio of Area under the curve from 0 to 12 hours (AUC0-12h) for doxycycline on Days 8 and 38</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence testing was constructed using paired two one-sided t-tests (TOST) with natural log transformation of PK parameters. Results obtained from transformed analyses were back-transformed by exponentiation for presentation of the point estimates and 90% CIs for geometric mean ratio of AUC0-12h.</non_inferiority_desc>
            <param_type>Ratio of AUC</param_type>
            <param_value>0.9173</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8187</ci_lower_limit>
            <ci_upper_limit>1.0278</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Analysis of Geometric mean ration of Cmax for doxycycline on Days 8 and 38</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence testing was constructed using paired two one-sided t-tests (TOST) with natural log transformation of PK parameters. Results obtained from transformed analyses were back-transformed by exponentiation for presentation of the point estimates and 90% CIs for geometric mean ratio of Cmax.</non_inferiority_desc>
            <param_type>Ratio of Cmax</param_type>
            <param_value>0.8974</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7841</ci_lower_limit>
            <ci_upper_limit>1.0271</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean TNA 50% Neutralizing Factor (NF50) Values Two Weeks After the Second AV7909 Vaccination (Day 37 ± 1 Day).</title>
        <description>Immunogenicity response as assessed by geometric mean of TNA NF50 values at Day 37 (two weeks after second dose of AV7909 vaccination).</description>
        <time_frame>Day 37 ± 1 day</time_frame>
        <population>The number of analyzed participants represents the number of participants that met pre-specified protocol criteria for inclusion in the immunogenicity analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1:Ciprofloxacin + AV7909</title>
            <description>Group 1 concomitantly received ciprofloxacin. Ciprofloxacin 500Mg Tablet: Ciprofloxacin 500mg was administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 4-9, 22-24 and 31-37.&#xD;
AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Doxycycline +AV7909</title>
            <description>Group 2 concomitantly received doxycycline. Doxycycline 100mg Tablet: Doxycycline 100mg was administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 2-9, 22-24 and 32-38.&#xD;
AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: AV7909</title>
            <description>AV7909: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean TNA 50% Neutralizing Factor (NF50) Values Two Weeks After the Second AV7909 Vaccination (Day 37 ± 1 Day).</title>
          <description>Immunogenicity response as assessed by geometric mean of TNA NF50 values at Day 37 (two weeks after second dose of AV7909 vaccination).</description>
          <population>The number of analyzed participants represents the number of participants that met pre-specified protocol criteria for inclusion in the immunogenicity analysis population.</population>
          <units>TNA NF50 titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.3" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.4" upper_limit="2.3"/>
                    <measurement group_id="O3" value="1.6" lower_limit="1.3" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT (Group 1/Group 3)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT (Group 2/Group 3)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Incidence of adverse events (AEs) from the first dose of any study treatment (either antibiotic and/or AV7909 vaccine) through the Final Study Visit (Day 51 ± 1 day)</time_frame>
      <desc>Safety in all groups were assessed up to Day 51 (last in-clinic visit) by collecting adverse events (AEs; including serious adverse event), local and systemic reactogenicity events and assessments of physical examinations, vital signs, clinical laboratories (hematology, serum chemistry, urinalysis). Only participants that received at least one dose of study treatment are included in the safety population (i.e., 62 participants in Group 1; 64 participants in Group 2; 64 participants in Group 3).</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Ciprofloxacin + AV7909</title>
          <description>Group 1 concomitantly received ciprofloxacin and AV7909.&#xD;
Ciprofloxacin 500 mg Tablet: Ciprofloxacin 500 mg administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 4-9, 22-24 and 31-37.&#xD;
AV7909: 0.5 mL AVA and 0.25mg CPG 7909 per 0.5 mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Doxycycline +AV7909</title>
          <description>Group 2 concomitantly received doxycycline and AV7909.&#xD;
Doxycycline 100 mg Tablet: Doxycycline 100 mg administered by mouth every 12 hours. The antibiotic was administered orally on Study Days 2-9, 22-24 and 32-38.&#xD;
AV7909: 0.5 mL AVA and 0.25mg CPG 7909 per 0.5 mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: AV7909</title>
          <description>AV7909: 0.5 mL AVA and 0.25mg CPG 7909 per 0.5 mL dose. The vaccine was administered intramuscularly on Study Days 8 and 23.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No Limitations and Caveats in the study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bojan Drobic, Director, Clinical Research</name_or_title>
      <organization>Emergent Biosolutions</organization>
      <phone>+1 (204) 275-4196</phone>
      <email>bdrobic@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

